Drug Interactions between methylnaltrexone and niraparib
This report displays the potential drug interactions for the following 2 drugs:
- methylnaltrexone
- niraparib
Interactions between your drugs
methylnaltrexone niraparib
Applies to: methylnaltrexone and niraparib
MONITOR: Coadministration with niraparib may increase the plasma concentrations of drugs that are substrates of the multidrug and toxin extrusion (MATE) 1 and/or 2 transporters. The proposed mechanism is MATE 1 and/or 2 inhibition by niraparib. However, the clinical significance of this interaction is unclear.
MANAGEMENT: Caution is recommended if niraparib is used in combination with substrates of the multidrug and toxin extrusion (MATE) 1 and/or 2 transporters like metformin. Monitoring for signs and symptoms of increased exposure to the MATE 1 and 2 substrates should be considered whenever niraparib is added to or withdrawn from therapy.
References (6)
- (2023) "Product Information. Akeega (abiraterone-niraparib)." Janssen Biotech, Inc.
- (2023) "Product Information. Zejula (niraparib)." GlaxoSmithKline
- (2023) "Product Information. Zejula (niraparib)." GlaxoSmithKline Inc
- (2023) "Product Information. Akeega (abiraterone-niraparib)." Janssen Inc
- (2023) "Product Information. Zejula (niraparib)." GlaxoSmithKline Australia Pty Ltd
- (2023) "Product Information. Zejula (niraparib)." GlaxoSmithKline UK Ltd
Drug and food interactions
methylnaltrexone food
Applies to: methylnaltrexone
ADJUST DOSING INTERVAL: Food may reduce the rate and extent of absorption of methylnaltrexone following oral administration. When a single 450 mg oral dose of methylnaltrexone was administered with a high-fat breakfast (approximately 800 to 1000 calories; 60% from fat, 25% from carbohydrate, and 15% from protein) in healthy study subjects, methylnaltrexone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 60% and 43%, respectively, while time to reach Cmax delayed by 2 hours.
MANAGEMENT: Oral methylnaltrexone should be taken with water on an empty stomach at least 30 minutes before the first meal of the day.
References (1)
- (2008) "Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.